Intended for healthcare professionals

Letters Second generation antidepressants

Author’s reply to Straton

BMJ 2012; 344 doi: (Published 27 March 2012) Cite this as: BMJ 2012;344:e2284
  1. Gerald Gartlehner, clinical epidemiologist1
  1. 1RTI-UNC Evidence-based Practice Center (USA), Austrian Cochrane Branch, 3500 Krems, Austria
  1. gerald.gartlehner{at}

Straton raises an interesting point, but his conclusion loses sight of an important factor in any statistical analysis—uncertainty.1 2 All fluvoxamine comparisons (in our 2008 and 2011 reviews) are encompassed by substantial uncertainty, as shown by …

View Full Text

Log in

Log in through your institution


* For online subscription